Wells Fargo & Company Eliem Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 3,149 shares of ELYM stock, worth $25,129. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,149
Previous 50
6198.0%
Holding current value
$25,129
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ELYM
# of Institutions
46Shares Held
49.9MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$251 Million3.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.9MShares$31.2 Million0.91% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.26MShares$26 Million11.93% of portfolio
-
Janus Henderson Group PLC London, X03.25MShares$26 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA2.6MShares$20.8 Million1.03% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $212M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...